Senator Jeff Stone was elected to represent the 28th State Senate District in 2014. The 28th District stretches from Southwest Riverside County (Temecula, Murrieta and Lake Elsinore) all the way to the Arizona Border.
In 1983, he opened his first small business the “Temecula Pharmacy” and began building his strong ties and local involvement within the community.
As a State Senator, he embraces the philosophy of a fiscally responsible and more efficient government that is less intrusive and more productive for its citizens. Senator Stone championed many efforts to stop over $30 billion in new taxes on the citizens of California.
Senator Stone has had important bills signed into law including the new prescription drug take back law which goes into effect January 1, 2016 which allows anyone to go into a participating pharmacy and at no charge to them, and drop their unused pharmaceuticals in a specially designed storage container.
In addition to his work in government, Senator Stone continues to own and operate his local business, Innovative Compounding Pharmacy. Senator Stone is a graduate of USC, where he earned a Doctor of Pharmacy degree. He has taught graduate nursing students seeking their masters in nursing degrees at Cal State Dominguez Hills as an assistant professor of pharmacology and also served as an externship professor for the USC School of Pharmacy.
Ezra Cohen, MD, is a board-certified oncologist and cancer researcher. He cares for patients with all types of head and neck cancers, including esophageal, thyroid and salivary gland cancers.
Dr. Cohen is also an internationally recognized expert on novel cancer therapies and heads the Solid Tumor Therapeutics program at Moores Cancer Center. Much of his work has focused on squamous cell carcinomas and cancers of the thyroid, salivary gland, and HPV-related oropharyngeal cancers. As a physician-scientist, he is especially interested in developing novel therapies and understanding mechanisms of sensitivity or resistance; cancer screening; and using medication and other agents to delay or prevent cancer (chemoprevention). He was recently appointed chair of the National Cancer Institute Head and Neck Cancer Steering Committee, which oversees NCI-funded clinical research in this disease.
Sandip Patel, MD, is a board-certified medical oncologist who specializes in cancer immunotherapy and early phase clinical trials involving immunotherapy across all types of cancer. Dr. Patel is focused on developing personalized therapies that stimulate a patient’s immune system to attack their specific tumor. He believes in offering these promising immunotherapeutics across all tumor types.
As an assistant professor in the Department of Medicine, Dr. Patel instructs medical students, residents and fellows. His research focuses on developing biomarkers for personalized immunotherapy to better determine which combination of therapies works best for each individual.
Shumei Kato, MD, is a board-certified medical oncologist who specializes in treating rare cancers and gastrointestinal tumors. He uses numerous forms of therapy such as chemotherapy, biological therapy, immunotherapy and targeted therapy to offer the best possible treatment options for his patients. Dr. Kato has a special interest in targeted molecular therapy and his approach to care emphasizes personalized medicine and experimental therapeutics.
As an assistant professor in the Department of Medicine, Dr. Kato instructs medical students, residents and fellows. His research interests include clinical trials and the design of new, more effective drugs for individualized therapy.
Dr. Kato has coauthored peer-reviewed articles, which have been published in Nature Cell Biology and the Journal of the National Cancer Institute, among others.
He is a member of the American Society of Clinical Oncology and the American Association for Cancer Research.
To update state and federal law to more closely align and promote future cancer treatments, resulting in saving or prolonging more cancer patients' lives.
The initial goal for Tonya's Law is to become a 2018 California Law. Tonya's Law will require tumor profiling with tests such as DNA sequencing for patients be covered by all insurance companies.
Copyright 2017 Tonya's Law. All rights reserved